Why access disparities show up here specifically
GLP-1 medications sit at the intersection of several factors that already produce unequal healthcare access in the U.S. — high list price, inconsistent insurance coverage, and reliance on specialist or well-resourced primary care to prescribe and manage treatment. That combination tends to compound existing income and racial disparities in healthcare access rather than existing independently of them.
What drives the disparity
- Insurance type and employer. As covered in our guide on employer self-funded plan decisions, whether GLP-1 coverage is offered often depends on employer choice — and higher-wage jobs are more likely to offer generous benefits packages that include it.
- Ability to pay out-of-pocket during gaps. Even with eventual coverage, prior authorization delays or temporary denials often require bridging the gap with out-of-pocket payment or manufacturer savings programs — an option not equally available to everyone.
- Access to prescribers who prescribe GLP-1s regularly. Primary care access varies significantly by region and insurance type, and areas with fewer providers experienced in obesity medicine create an access bottleneck independent of insurance coverage itself.
- Health literacy and navigation capacity. Successfully navigating prior authorization, appeals, and formulary research (see our guide on checking your formulary) takes time, persistence, and comfort with bureaucratic systems — resources that are not equally distributed.